University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 2N-19-1


A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Bing Xia, M.D.
Other Trial Staff:  Victoria Amran, D.M., Grace Facio, Coordinator, Marissa Aldana, D.M., Mary Ordaz, D.M., Margarita Carranza, D.M., Gina Tse, Coordinator, Eduardo Mejia, D.M., America Casillas-Lopez, Coordinator, Laurie De Oliveira, Coordinator, Niranjan Bhatt, D.M., Alix Cohen, Coordinator, Brigitte Torres, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.